Newbury Pharmaceuticals

Bifogade filer

Regulatory Filing for Teduglutide

Kurs

+5,16%

Likviditet

0,25 MSEK

Prenumeration

Kalender

	Est. tid*
2027-01-21	N/A	X-dag ordinarie utdelning NEWBRY 0.00 SEK
2027-01-20	N/A	Årsstämma
2027-01-20	08:00	Kvartalsrapport 2027-Q1
2026-10-28	08:00	Bokslutskommuniké 2026
2026-07-08	08:00	Kvartalsrapport 2026-Q3
2026-04-15	08:00	Kvartalsrapport 2026-Q2
2026-01-21	08:00	Kvartalsrapport 2026-Q1
2026-01-14	N/A	Årsstämma
2025-10-29	-	Bokslutskommuniké 2025
2025-07-09	-	Kvartalsrapport 2025-Q3
2025-04-09	-	Kvartalsrapport 2025-Q2
2025-01-24	-	Kvartalsrapport 2025-Q1
2025-01-16	-	X-dag ordinarie utdelning NEWBRY 0.00 SEK
2025-01-15	-	Årsstämma
2024-10-23	-	Bokslutskommuniké 2024
2024-07-31	-	Extra Bolagsstämma 2024
2024-07-10	-	Kvartalsrapport 2024-Q3
2024-04-10	-	Kvartalsrapport 2024-Q2
2024-01-11	-	X-dag ordinarie utdelning NEWBRY 0.00 SEK
2024-01-10	-	Årsstämma
2024-01-10	-	Kvartalsrapport 2024-Q1
2023-10-11	-	Bokslutskommuniké 2023
2023-07-14	-	Kvartalsrapport 2023-Q3
2023-04-12	-	Kvartalsrapport 2023-Q2
2023-01-12	-	X-dag ordinarie utdelning NEWBRY 0.00 SEK
2023-01-11	-	Årsstämma
2023-01-11	-	Kvartalsrapport 2023-Q1
2022-10-13	-	Bokslutskommuniké 2022
2022-07-06	-	Kvartalsrapport 2022-Q3
2022-04-13	-	Kvartalsrapport 2022-Q2

Beskrivning

Land	Sverige
Lista	First North Stockholm
Sektor	Hälsovård
Industri	Läkemedel & Handel

Newbury Pharmaceuticals är verksamt inom läkemedelsbranschen. Bolaget utvecklar en pipeline av egenutvecklade och licensierade produkter med fokus på specialläkemedel inom områden som onkologi, sällsynta sjukdomar och neurologi. Bolaget bedriver sin verksamhet inom den skandinaviska marknaden. Newbury Pharmaceuticals grundades år 2020 och har sitt huvudkontor i Lund.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Regulatory Filing for Teduglutide

2024-09-13 11:30:00

Newbury has through one of its partners initiated a DCP filing for Teduglutide on Day-1 following the expiry of Data Exclusivity.

Teduglutide has been developed for the treatment of short bowel syndrome (SBS), a rare condition that impairs the small intestine’s ability to properly absorb nutrients and fluids.

This submission presents a first-to-market opportunity for Newbury, emphasizing our commitment to addressing unmet medical needs in the rare disease segment. Launch is anticipated to take place in 2026.

Teduglutide achieved a turnover of approximately 10 M€ in the Nordics during the past 12 months, according to DLMI (MAT August 2024).

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Newbury Pharmaceuticals

Bifogade filer

Kurs +5,16%

Likviditet 0,25 MSEK